Paratope and Epitope Mapping of the Antithrombotic Antibody 6B4 in Complex with Platelet Glycoprotein Ibα

Alexandre Fontayne, Bauke De Maeyer, Marc De Maeyer, Mayo Yamashita, Tadashi Matsushita, Hans Deckmyn

Journal of Biological Chemistry · 2007 · 25 citations · 20 references

DOIFull text

Open access

Concepts

Abstract

The monoclonal antibody 6B4 has a potent antithrombotic effect in nonhuman primates by binding to the flexible loop, also known as the β-switch region (amino acids 230-242), of glycoprotein Ibα (GPIbα). This interaction blocks, in high shear stress conditions, the specific interaction between GPIbα and von Willebrand factor suppressing platelet deposition to the damaged vessel wall, a key event in the pathogenesis of arterial thrombosis. To understand the interactions between this antibody and its antigen at the amino acid level, we here report the identification of the paratope and epitope in 6B4 and GPIbα, respectively, by using computer modeling and site-directed mutagenesis. The docking programs ZDOCK (rigid body docking) and HADDOCK (flexible docking) were used to model the interaction of 6B4 with GPIbα and to delineate the respective paratope and epitope. 6B4 and GPIbα mutants were constructed and assayed for their capacity to bind GPIbα and 6B4, respectively. From these data, it is found that the paratope of 6B4 is mainly formed by five residues: Tyr27D, Lys27E, Asp28, and Glu93 located in light chain CDR1 and -3, respectively, and Tyr100C of the heavy chain CDR3. These residues form a valley, where the GPIbα flexible loop can bind via residues Asp235 and Lys237. The experimental results were finally used to build a more accurate docking model. Taken together, this information provides guidelines for the design of new derivatized lead compounds with antithrombotic properties. The monoclonal antibody 6B4 has a potent antithrombotic effect in nonhuman primates by binding to the flexible loop, also known as the β-switch region (amino acids 230-242), of glycoprotein Ibα (GPIbα). This interaction blocks, in high shear stress conditions, the specific interaction between GPIbα and von Willebrand factor suppressing platelet deposition to the damaged vessel wall, a key event in the pathogenesis of arterial thrombosis. To understand the interactions between this antibody and its antigen at the amino acid level, we here report the identification of the paratope and epitope in 6B4 and GPIbα, respectively, by using computer modeling and site-directed mutagenesis. The docking programs ZDOCK (rigid body docking) and HADDOCK (flexible docking) were used to model the interaction of 6B4 with GPIbα and to delineate the respective paratope and epitope. 6B4 and GPIbα mutants were constructed and assayed for their capacity to bind GPIbα and 6B4, respectively. From these data, it is found that the paratope of 6B4 is mainly formed by five residues: Tyr27D, Lys27E, Asp28, and Glu93 located in light chain CDR1 and -3, respectively, and Tyr100C of the heavy chain CDR3. These residues form a valley, where the GPIbα flexible loop can bind via residues Asp235 and Lys237. The experimental results were finally used to build a more accurate docking model. Taken together, this information provides guidelines for the design of new derivatized lead compounds with antithrombotic properties. Platelets are a key factor in hemostasis (1Ruggeri Z.M. Thromb. Haemostasis. 1997; 78: 611-616Crossref PubMed Scopus (324) Google Scholar). However, in some pathological situations, such as stroke or myocardial infarction, shear rate increases, causing platelet activation and thrombus formation, leading to vessel occlusion. This process is dependent on the binding of the platelet glycoprotein Ibα (GPIbα) 4The abbreviations used are: GPIbα, glycoprotein Ibα; VWF, von Willebrand factor; LRR, leucine-rich repeat; CDR, complementarity determining region; Ab, antibody; mAb, monoclonal antibody; WT, wild type. to von Willebrand factor (VWF), which is bound to the collagen matrix exposed to the flowing blood upon vessel damage. The structure of GPIbα consists of a globular N-terminal region, a sialomucin core, an anionic sequence, a transmembrane region, and a cytoplasmic tail. The N-terminal region (residues 1-282) consists of eight leucine-rich repeats (LRRs) and contains the binding sites for VWF, α-thrombin, P-selectin, Mac-1, high molecular weight kininogen, and coagulation factors XI and XII (2Andrews R.K. Lopez J.A. Berndt M.C. Int. J. Biochem. Cell Biol. 1997; 29: 91-105Crossref PubMed Scopus (180) Google Scholar, 3Berndt M.C. Shen Y. Dopheide S.M. Gardiner E.E. Andrews R.K. Thromb. Haemost. 2001; 86: 178-188Crossref PubMed Scopus (244) Google Scholar, 4Yip J. Shen Y. Berndt M.C. Andrews R.K. IUBMB Life. 2005; 57: 103-108Crossref PubMed Scopus (57) Google Scholar). Under nonliganded conditions, platelets present the flexible loop (residues 230-242) within the N-terminal domain of GPIbα into a β-switch conformation, which changes upon binding of VWF into a β-hairpin conformation, extending the existing VWF antiparallel β-sheet (5Huizinga E.G. Tsuji S. Romijn R.A. Schiphorst M.E. de Groot P.G. Sixma J.J. Gros P. Science. 2002; 297: 1176-1179Crossref PubMed Scopus (501) Google Scholar). The GPIbα gain-of-function mutations G233V and M239V found in platelet-type von Willebrand disease stabilize the β-hairpin conformation and increase the affinity of GPIbα for VWF 5-6-fold (4Yip J. Shen Y. Berndt M.C. Andrews R.K. IUBMB Life. 2005; 57: 103-108Crossref PubMed Scopus (57) Google Scholar, 6Andrews R.K. Gardiner E.E. Shen Y. Whisstock J.C. Berndt M.C. Int. J Biochem. Cell Biol. 2003; 35: 1170-1174Crossref PubMed Scopus (168) Google Scholar). The globular domain is presented well above the plasma membrane by the sialomucin core, which is connected by a flexible hinge domain: the anionic sequence. The cytoplasmic tail of GPIbα contains binding sites for filamin A and 14-3-3 ζ, which play an important role in intracellular signaling upon ligand binding (3Berndt M.C. Shen Y. Dopheide S.M. Gardiner E.E. Andrews R.K. Thromb. Haemost. 2001; 86: 178-188Crossref PubMed Scopus (244) Google Scholar, 7Feng S. Resendiz J.C. Lu X. Kroll M.H. Blood. 2003; 102: 2122-2129Crossref PubMed Scopus (75) Google Scholar, 8Nakamura F. Pudas R. Heikkinen O. Permi P. Kilpelainen I. Munday A.D. Hartwig J.H. Stossel T.P. Ylanne J. Blood. 2006; 107: 1925-1932Crossref PubMed Scopus (136) Google Scholar). Previously, we prepared and characterized a murine monoclonal antibody (mAb) targeting the human GPIbα, designated as 6B4 (9Cauwenberghs N. Meiring M. Vauterin S. van Wyk V. Lamprecht S. Roodt J.P. Novak L. Harsfalvi J. Deckmyn H. Kotze H.F. Arterioscler. Thromb. Vasc. Biol. 2000; 20: 1347-1353Crossref PubMed Scopus (124) Google Scholar). This mAb inhibits platelet adhesion under high shear stress conditions, as was shown in flow chambers (10Cauwenberghs N. Vanhoorelbeke K. Vauterin S. Westra D.F. Romo G. Huizinga E.G. Lopez J.A. Berndt M.C. Harsfalvi J. Deckmyn H. Blood. 2001; 98: 652-660Crossref PubMed Scopus (79) Google Scholar). Injection of 6B4-Fab fragments has a potent in vivo antithrombotic effect in baboons (9Cauwenberghs N. Meiring M. Vauterin S. van Wyk V. Lamprecht S. Roodt J.P. Novak L. Harsfalvi J. Deckmyn H. Kotze H.F. Arterioscler. Thromb. Vasc. Biol. 2000; 20: 1347-1353Crossref PubMed Scopus (124) Google Scholar, 11Wu D. Meiring M. Kotze H.F. Deckmyn H. Cauwenberghs N. Arterioscler. Thromb. Vasc. Biol. 2002; 22: 323-328Crossref PubMed Scopus (70) Google Scholar) but also on inhibiting ex vivo ristocetin-induced platelet aggregation (9Cauwenberghs N. Meiring M. Vauterin S. van Wyk V. Lamprecht S. Roodt J.P. Novak L. Harsfalvi J. Deckmyn H. Kotze H.F. Arterioscler. Thromb. Vasc. Biol. 2000; 20: 1347-1353Crossref PubMed Scopus (124) Google Scholar). Contrary to most antithrombotic drugs, 6B4-Fab administration did not induce a significant prolongation of the bleeding time. The epitope recognized by 6B4 was mapped previously, using human/canine chimeric rGPIbα, to be within the C-terminal flanking region, between residues 201 and 268 (10Cauwenberghs N. Vanhoorelbeke K. Vauterin S. Westra D.F. Romo G. Huizinga E.G. Lopez J.A. Berndt M.C. Harsfalvi J. Deckmyn H. Blood. 2001; 98: 652-660Crossref PubMed Scopus (79) Google Scholar), containing the flexible loop (residue 230-242) within the N-terminal domain of GPIbα.An indication that upon binding of 6B4, this loop might not assume the β-hairpin conformation, as seen upon binding of VWF, comes from the finding that 6B4 no longer binds to the gain-of-function G233V and M239V (5Huizinga E.G. Tsuji S. Romijn R.A. Schiphorst M.E. de Groot P.G. Sixma J.J. Gros P. Science. 2002; 297: 1176-1179Crossref PubMed Scopus (501) Google Scholar, 10Cauwenberghs N. Vanhoorelbeke K. Vauterin S. Westra D.F. Romo G. Huizinga E.G. Lopez J.A. Berndt M.C. Harsfalvi J. Deckmyn H. Blood. 2001; 98: 652-660Crossref PubMed Scopus (79) Google Scholar). The goal of this study was to further determine which residues are involved in the binding of 6B4 to GPIbα. Docking approaches using computer programs such as ZDOCK (12Chen R. Weng Z. Proteins. 2002; 47: 281-294Crossref PubMed Scopus (310) Google Scholar), an algorithm more appropriate as an initial stage docking algorithm to explore vast putative binding areas in cases were the target binding site is unknown or less defined, and the HADDOCK1.3 method, which allows flexibility (13Russell R.B. Alber F. Aloy P. Davis F.P. Korkin D. Pichaud M. Topf M. Sali A. Curr. Opin. Struct. Biol. 2004; 14: 313-324Crossref PubMed Scopus (227) Google Scholar, 14Dominguez C. Boelens R. Bonvin A.M. J Am. Chem. Soc. 2003; 125: 1731-1737Crossref PubMed Scopus (2188) Google Scholar, 15Bonvin A.M. Curr. Opin. Struct. Biol. 2006; 16: 194-200Crossref PubMed Scopus (257) Google Scholar) in both ligand and target, were used to predict interactions between ligand-bound or ligand-free GPIbα and various models of 6B4, followed by mutagenesis experiments in an iterative approach. By this method, we identified residues in the complementarity determining regions (CDRs) of 6B4, crucial for the binding and constituting its paratope. In parallel, the epitope mapping on the flexible loop of GPIbα was confirmed and refined. An optimized interaction model was finally constructed combining all of the findings. Materials—Protein A-Sepharose CL-4B and ECL™ were purchased from Amersham Biosciences. The QuikChange XL site-directed mutagenesis kit was provided by Stratagene (La Jolla, CA), and the DNA sequencing was performed by Genome Express (Meylan, France). Primer sequences listed in Table 1 were purchased from Eurogentec (Seraing, Belgium). Cell culture products for the IgG4 expression and Lipofectamine 2000™ were provided by Invitrogen. Centriprep-30 and Centricon-100 devices were provided by Millipore (Billerica, MA). The monoclonal anti-human IgG4, Fc-specific Ab was from BD Pharmigen (San Diego, CA), the anti-human IgG horseradish peroxidase-labeled Ab was purchased from Imtec Diagnostic (Antwerpen, Belgium), and the goat anti-mouse horseradish peroxidase-labeled Ab and the orthophenylenediamine were from Sigma.TABLE 1Candidate residues for mutagenesisMutantaMutated residues are located on the variable domain of the light (VL) or heavy (VH) chain of 6B4-IgG4. The name of the mutant includes the WT residue followed by its in an followed by the of the mutant The for the changes and the for the is also for of the used to light or heavy chain mutants of The with the of or used for the of 6B4 The and the of of of of of of residues are located on the variable domain of the light (VL) or heavy (VH) chain of 6B4-IgG4. The name of the mutant includes the WT residue followed by its in an followed by the of the mutant The for the changes and the for the is also of the used to light or heavy chain mutants of A. Vanhoorelbeke K. I. Meiring M. Lamprecht S. Roodt J. J. Deckmyn H. Haemost. 2006; PubMed Scopus Google Scholar). The with the of or used for the of 6B4 The and the in a new of the 6B4-Fab to GPIbα (amino acids was performed using the ZDOCK (12Chen R. Weng Z. Proteins. 2002; 47: 281-294Crossref PubMed Scopus (310) Google Scholar) and HADDOCK1.3 C. Boelens R. Bonvin A.M. J Am. Chem. Soc. 2003; 125: 1731-1737Crossref PubMed Scopus (2188) Google Scholar). were with the modeling P. M. M. M. D. J. I. P. J. Google Scholar). The for the docking were computer models of model was by A. Vanhoorelbeke K. I. Meiring M. Lamprecht S. Roodt J. J. Deckmyn H. Haemost. 2006; PubMed Scopus Google Scholar), and models were from the 2000; PubMed Scopus Google Scholar), the structure of the ligand-free conformation of GPIbα (5Huizinga E.G. Tsuji S. Romijn R.A. Schiphorst M.E. de Groot P.G. Sixma J.J. Gros P. Science. 2002; 297: 1176-1179Crossref PubMed Scopus (501) Google Scholar) and the structure of the ligand-bound conformation of GPIbα J.J. R. F. L. J. Biol. Chem. 2004; PubMed Scopus Google Scholar). The HADDOCK to information from all models in the was a to the a of interaction sites was HADDOCK the residues into which play an important role in and which be involved in the the mAb it is that the are involved in the experimental that in GPIbα, loop flexible loop at amino acids is involved in the binding (10Cauwenberghs N. Vanhoorelbeke K. Vauterin S. Westra D.F. Romo G. Huizinga E.G. Lopez J.A. Berndt M.C. Harsfalvi J. Deckmyn H. Blood. 2001; 98: 652-660Crossref PubMed Scopus (79) Google Scholar). The residues of the and the GPIbα flexible loop were as residues in the docking The ZDOCK (12Chen R. Weng Z. Proteins. 2002; 47: 281-294Crossref PubMed Scopus (310) Google Scholar) and site-directed mutagenesis that and M. of of of in the light chain CDR1 and -3, respectively, to the these residues were as In the docking the variable of the mAb were these were not were used to the light and heavy the of the and of 6B4, and were in human GPIbα (9Cauwenberghs N. Meiring M. Vauterin S. van Wyk V. Lamprecht S. Roodt J.P. Novak L. Harsfalvi J. Deckmyn H. Kotze H.F. Arterioscler. Thromb. Vasc. Biol. 2000; 20: 1347-1353Crossref PubMed Scopus (124) Google Scholar), by affinity with A-Sepharose and at was by under conditions, followed by were by at and were at and of 6B4 WT and 6B4 WT and mutants were prepared as chimeric IgG4 as A. Vanhoorelbeke K. I. Meiring M. Lamprecht S. Roodt J. J. Deckmyn H. Haemost. 2006; PubMed Scopus Google Scholar). of 6B4 mutants was performed with the QuikChange XL site-directed mutagenesis kit to the using and for the respective chimeric light and heavy chain of 6B4, and the appropriate and for the of DNA were and their DNA was 6B4 were in a expression using human and Lipofectamine 2000™ as A. Vanhoorelbeke K. I. Meiring M. Lamprecht S. Roodt J. J. Deckmyn H. Haemost. 2006; PubMed Scopus Google Scholar). and of 6B4 WT and were on a A-Sepharose CL-4B and at was performed by and using a monoclonal anti-human Ab, followed by goat anti-mouse horseradish peroxidase-labeled Ab using was in with an IgG4 by using anti-human Ab for and an anti-human IgG horseradish peroxidase-labeled Ab for mAb were to 1 and at and of and mutant were in a expression using and Lipofectamine in the was using Centriprep-30 and Centricon-100 The of mutant was by a as A. Y. H. M. J. Biol. Chem. 2004; PubMed Scopus Google Scholar). of 6B4 WT and to capacity of WT and mutant 6B4 to bind to platelets was in an where the antibody was in a of into with human platelets A. Vanhoorelbeke K. I. Meiring M. Lamprecht S. Roodt J. J. Deckmyn H. Haemost. 2006; PubMed Scopus Google Scholar). was by with a monoclonal antibody followed by a goat anti-mouse horseradish peroxidase-labeled Ab the of and with and on a of 6B4 WT at was as of WT and to GPIbα WT and mutants were for their capacity to bind to monoclonal 6B4, and in an as A. Y. H. M. J. Biol. Chem. 2004; PubMed Scopus Google Scholar). binding capacity of 6B4 and its mutants to GPIbα as well as the binding of GPIbα and its mutants to monoclonal GPIbα were by The were significant was 6B4 paratope was by computer models of the variable regions of 6B4 bound to of GPIbα. In a a 6B4 computer model A. Vanhoorelbeke K. I. Meiring M. Lamprecht S. Roodt J. J. Deckmyn H. Haemost. 2006; PubMed Scopus Google Scholar) was to the ligand-free conformation of GPIbα using the ZDOCK (12Chen R. Weng Z. Proteins. 2002; 47: 281-294Crossref PubMed Scopus (310) Google Scholar). The model was characterized by binding site in which the mAb binds to the flexible loop of GPIbα. The model that both the light and heavy chain of 6B4 to the binding to GPIbα. on this 6B4 residues were for to on the light chain and and on the heavy chain and of and to were as no effect was and were found to the binding of 6B4 to GPIbα A and the body docking ZDOCK the of in a used the results from the as to a new docking model using HADDOCK1.3 that allows for flexible docking in both 6B4 and GPIbα. used the of the mAb the ligand-free and ligand-bound of GPIbα in the docking The docking of 6B4 to the ligand-bound conformation of GPIbα did not between the were found that mainly between chain not The docking results with the ligand-free GPIbα structure were into which are as an of at a at the C. Boelens R. Bonvin A.M. J Am. Chem. Soc. 2003; 125: 1731-1737Crossref PubMed Scopus (2188) Google Scholar). the models in of the docking model in 1 was both and Glu93 are to bind GPIbα, which is in with experimental on this docking light chain Asp28, and and heavy chain and were for mutagenesis from the HADDOCK docking of the 6B4 model to the conformation of in a new In this of which are with the of and located in the GPIbα and respectively. To these was not to but also to the also in this model in most is to play an important role in it interactions with and of GPIbα and In the of to did not the binding of 6B4 to GPIbα also here we a mutant in which the is 6B4 for which was in were for their capacity to bind to human platelets the five new mutants bound to GPIbα on that mutants and from 1 and and from at and binding of 6B4 to GPIbα, the mutants and from 1 and from on the mutagenesis data, we can that residues Tyr27D, Lys27E, and of Glu93 of and Tyr100C of are of the paratope of 6B4 The not to be involved in the and between 6B4 and GPIbα in model of the residues in 6B4 are in of the residues in 6B4 are in in a new on on the docking model of 6B4 bound to GPIbα, a of residues were to be of the epitope. residues present at the antigen and or interactions with residues of 6B4 be putative residues of the epitope of these residues are located in the and residues involved and are of the β-switch region, the key that changes its conformation ligand binding (5Huizinga E.G. Tsuji S. Romijn R.A. Schiphorst M.E. de Groot P.G. Sixma J.J. Gros P. Science. 2002; 297: 1176-1179Crossref PubMed Scopus (501) Google Scholar). To a of to GPIbα mutants A. Y. H. M. J. Biol. Chem. 2004; PubMed Scopus Google Scholar) containing residues to was for the binding to wild an were which with 6B4 for the binding to human platelets (10Cauwenberghs N. Vanhoorelbeke K. Vauterin S. Westra D.F. Romo G. Huizinga E.G. Lopez J.A. Berndt M.C. Harsfalvi J. Deckmyn H. Blood. 2001; 98: 652-660Crossref PubMed Scopus (79) Google Scholar), and N. N. Vauterin S. D. Deckmyn H. Haemostasis. 2000; Google Scholar), which not of 6B4, and on GPIbα. involved in 6B4 not to of the gain-of-function mutations that 6B4 binding of monoclonal to mutant GPIbα. expression and GPIbα was for the binding to mAb 6B4, or as under the with for at with with in are under and to the in Table of the N-terminal of GPIbα with residues involved or not in 6B4 and for which the gain-of-function to the binding of 6B4, are in The of the models with the were with on the A of the binding of mAb 6B4 was seen to GPIbα mutants and and and which all of the residues for and of which did not However, the binding of all and to the mutants was it is that these induce a in GPIbα, as A. Y. H. M. J. Biol. Chem. 2004; PubMed Scopus Google Scholar) and might an effect on the antibody These are with in the of the which on the Asp235 and of the β-switch region Docking of the results from the mutagenesis experiments on both 6B4 and GPIbα were and used for docking with using the 6B4 models and the ligand-free and ligand-bound GPIbα were by and to the and here the docking models be with the ligand-free GPIbα conformation, of which the and is to the model In model 6B4 is and into the N-terminal in an interaction from to the GPIbα the β-switch region has a conformation, leading to a in of between the and the β-switch The between the docking and is we the but we to the residues that are in the A of the docking models that some of the amino acids of 6B4 that were involved in the interaction of the docking model no longer are the new residues are in the and In model with residues and is of the from which it was in model In both docking the light chain has a role in the binding to GPIbα, is not The interaction of GPIbα in model not from the in model the N-terminal flanking region, the five and the β-switch region are all involved in the binding to a monoclonal 6B4, targeting the human GPIbα, which is for the binding of platelets to the exposed collagen in damaged via von Willebrand factor under high shear results in models of arterial we a and of at antithrombotic 6B4-Fab not the bleeding it induce (9Cauwenberghs N. Meiring M. Vauterin S. van Wyk V. Lamprecht S. Roodt J.P. Novak L. Harsfalvi J. Deckmyn H. Kotze H.F. Arterioscler. Thromb. Vasc. Biol. 2000; 20: 1347-1353Crossref PubMed Scopus (124) Google Scholar, 11Wu D. Meiring M. Kotze H.F. Deckmyn H. Cauwenberghs N. Arterioscler. Thromb. Vasc. Biol. 2002; 22: 323-328Crossref PubMed Scopus (70) Google Scholar). To of the in vivo of GPIbα, a for administration is a for a and a that we here identified the paratope of 6B4 that the of the In this we mapped both the paratope and the epitope of 6B4 by combining computer docking models with mutagenesis on both 6B4 and GPIbα. docking using 6B4 and GPIbα in its ligand-free conformation identified light chain residues and of the to be for the This might be to the that ZDOCK is an algorithm for body GPIbα, is a with known and also their residue to the affinity for their to this be to molecular followed by of binding with the molecular for Y. Z. H. D. X. H. J. 2004; PubMed Scopus Google Scholar) did to the interaction between the and the An which we is using a docking that allows flexibility in both ligand and target such as Docking were both the ligand-free and ligand-bound conformation of GPIbα in with 6B4 models constructed with the to the model that we used to a 6B4-Fab A. Vanhoorelbeke K. I. Meiring M. Lamprecht S. Roodt J. J. Deckmyn H. Haemost. 2006; PubMed Scopus Google Scholar). the and no models were identified with the ligand-bound conformation of GPIbα. This finding is in with where the binding of 6B4 was some to the of and GPIbα, as with the wild (10Cauwenberghs N. Vanhoorelbeke K. Vauterin S. Westra D.F. Romo G. Huizinga E.G. Lopez J.A. Berndt M.C. Harsfalvi J. Deckmyn H. Blood. 2001; 98: 652-660Crossref PubMed Scopus (79) Google Scholar). These of are found in platelet-type von Willebrand disease and the affinity of GPIbα for VWF R.K. Gardiner E.E. Shen Y. Whisstock J.C. Berndt M.C. Int. J Biochem. Cell Biol. 2003; 35: 1170-1174Crossref PubMed Scopus (168) Google Scholar, Thromb. Haemost. PubMed Scopus Google Scholar). the structure of GPIbα of these mutations is to its conformation in with the VWF domain J.J. R. F. L. J. Biol. Chem. 2004; PubMed Scopus Google Scholar). 6B4 residues involved in the binding to ligand-free GPIbα, as from the docking model were as The chimeric was it has the A. Vanhoorelbeke K. I. Meiring M. Lamprecht S. Roodt J. J. Deckmyn H. Haemost. 2006; PubMed Scopus Google Scholar) as the IgG and is to and to of the mutants in for the binding was for all mutants for experiments of 6B4 WT and its mutants were performed on platelets of GPIbα in the we identified paratope residues in and in and which all are in on the antibody To further docking model we the role of residue in GPIbα by using the A. Y. H. M. J. Biol. Chem. 2004; PubMed Scopus Google Scholar). of most of the residues However, a of these mutations are to induce a in GPIbα A. Y. H. M. J. Biol. Chem. 2004; PubMed Scopus Google Scholar), which also here in a binding of with (10Cauwenberghs N. Vanhoorelbeke K. Vauterin S. Westra D.F. Romo G. Huizinga E.G. Lopez J.A. Berndt M.C. Harsfalvi J. Deckmyn H. Blood. 2001; 98: 652-660Crossref PubMed Scopus (79) Google Scholar), we a on in to residues Asp235 and located in the β-switch region, which binding of These results are in with the study of Cauwenberghs (10Cauwenberghs N. Vanhoorelbeke K. Vauterin S. Westra D.F. Romo G. Huizinga E.G. Lopez J.A. Berndt M.C. Harsfalvi J. Deckmyn H. Blood. 2001; 98: 652-660Crossref PubMed Scopus (79) Google Scholar), where we used human/canine chimeric GPIbα to the epitope. we performed a new docking all known experimental data, which a model in with all of the mutagenesis In by the crucial residues involved in the interaction of 6B4 with GPIbα, a model of the at the is This information allows for a of the antithrombotic of 6B4 and be in the design of and in a the iterative we used here to the amino acid residues by docking and mutagenesis experiments allows for a more identification of residues a mutagenesis can and can be to interactions for which information is with

References

20